Cytotoxic effect of a new 1,3,4-thiadiazolium mesoionic compound (MI-D) on cell lines of human melanoma
Open Access
- 15 June 2004
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 91 (2) , 297-304
Abstract
The structural characteristics of mesoionic compounds, which contain distinct regions of positive and negative charges associated with a poly-heteroatomic system, enable them to cross cellular membranes and interact strongly with biomolecules. Potential biological applications have been described for mesoionic compounds. 1,3,4-Thiadiazolium mesoionic compound (MI-D), a new mesoionic compound, has been demonstrated to be extremely cytotoxic to B16-F10 murine melanoma cells when compared to fotemustine and dacarbazine, drugs of reference in melanoma treatment protocols, describing inhibition of tumours grown in vitro and in vivo. We now evaluate the effects of mesoionic compound MI-D on different human melanoma cell lines. The drug decreased the viability and proliferation of MEL-85, SK-MEL, A2058 and MEWO cell lines in vitro, showing a considerable cytotoxic activity on these human cells. Adhesion of MEL-85 cells was evaluated in the presence of the drug using different extracellular matrix (ECM) constituents. MI-D decreased MEL-85 adhesion to laminin, fibronectin and matrigel. The morphology and actin cytoskeleton organisation of MEL-85 cells were also modified on MI-D treatment. These results on human melanoma cell lines indicate that MI-D is a very encouraging drug against melanoma, a tumour that is extremely resistant to chemotherapy.Keywords
This publication has 36 references indexed in Scilit:
- Participation of Syndecan 2 in the Induction of Stress Fiber Formation in Cooperation with Integrin α5β1: Structural Characteristics of Heparan Sulfate Chains with Avidity to COOH-Terminal Heparin-Binding Domain of FibronectinExperimental Cell Research, 2000
- Entropy-Driven Interactions of Anesthetics with Membrane ProteinsBiochemistry, 1997
- Synthesis and in vivo antitumor activity of new heterocyclic derivatives of the 1,3,4-thiadiazolium-2-aminide classAnti-Cancer Drugs, 1997
- New NO‐Donors with Antithrombotic and Vasodilating Activities, XII: Mesoionic Oxatriazoles and Related Noncyclic Nitrosohydrazine DerivativesArchiv der Pharmazie, 1995
- Platelet Aggregation Inhibiting and Anticoagulant Effects of Oligoamines, XXVII Inhibition of Leucocyte Adherence to Endothelium by the Oligoamine RE 1492C and the NO-Donor RE 2047Archiv der Pharmazie, 1995
- Plasma Levels of Peptide YY Correlate with Cisplatin-induced Emesis in DogsJournal of Pharmacy and Pharmacology, 1994
- Several nongenotoxic carcinogens uncouple mitochondrial oxidative phosphorylationBiochimica et Biophysica Acta (BBA) - Bioenergetics, 1992
- Synthesis and Antimicrobial Activity of 3‐(Substituted‐phenyl)‐sydnonesArchiv der Pharmazie, 1992
- Laminin-nidogen complex. Extraction with chelating agents and structural characterizationEuropean Journal of Biochemistry, 1987
- Molsidomine in the Treatment of Patients with Angina PectorisNew England Journal of Medicine, 1980